EXAI חוב כולל להון Exscientia PLC

Exscientia plc (EXAI) develops innovative drug discovery software, where the primary growth drivers are algorithmic accuracy and the volume of contracts with major pharmaceutical companies. The high value of these technologies enables the business to secure significant milestone payments for successful developments. The current total debt-to-equity ratio stands at 0.07, which is clearly illustrated by the price chart used for the asset's baseline valuation.

Financial stability for Exscientia plc (EXAI) depends directly on its ability to cover AI development costs without excessive borrowing. This ratio compares total liabilities to equity, allowing GURU.Markets investors to use the debt-to-equity chart to assess the risk of default or underinvestment, given the company's reliance on partner payments and a high cash burn rate.